Every 8-K that Revelation Biosciences, Inc. (REVB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow REVB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full REVB filings page.
Revelation Biosciences, Inc. (REVB) disclosed that its Compensation Committee approved new Restricted Stock Awards for senior executives under the Amended and Restated 2021 Equity Incentive Plan, effective August 17, 2026. Chief Executive Officer James Rolke received 208,076 restricted shares and Chief Financial Officer Chester S. Zygmont, III received 208,073 restricted shares.
The awards vest in four equal 25% tranches based on the earlier of market capitalization milestones of $30 million, $60 million, $90 million, and $120 million sustained for twenty consecutive trading days, or time-based anniversaries at two and four years from grant. The awards fully vest immediately before a Change in Control, or upon certain terminations (death, termination without Cause, or resignation for Good Reason), and are otherwise forfeited if service ends under other circumstances. The form of Restricted Stock Award Agreement is filed as an exhibit.
Revelation Biosciences, Inc. reported financial results for the three and six months ended June 30, 2026 and highlighted progress on its Gemini programs. Net loss was $3,323,384, or $(0.87) per share, for the quarter and $6,332,435, or $(3.41) per share, for the six-month period.
Cash and cash equivalents were $11,482,792 as of June 30, 2026, compared with $10,700,331 at December 31, 2025, and the company expects this to fund operations through the first quarter of 2027. Total stockholders’ equity was $10,066,986, with 3,908,420 common shares outstanding. Operationally, Revelation advanced start-up activities for a Phase 2/3 acute kidney injury study of Gemini, formed and expanded an Acute Kidney Injury Advisory Board, and cited an independent assessment indicating a potential $94 billion total addressable market for Gemini.
Revelation Biosciences, Inc. adopted a stockholder rights plan via a Rights Agreement with Continental Stock Transfer & Trust Co. and declared a dividend of one preferred share purchase right for each outstanding common share to holders of record on July 21, 2026.
Each right, once exercisable, permits purchase of one one-thousandth of a share of Series B Junior Participating Preferred Stock at $20.00. The plan is triggered if a person or group acquires beneficial ownership of 10% or more of common stock (or 15% for qualifying passive investors) without prior Board approval, activating flip-in and potential flip-over protections against coercive control attempts. Before a trigger, the Board may redeem the rights for $0.001 per right. The rights expire on the first anniversary of the Rights Agreement or on the third anniversary if stockholders ratify it, subject to earlier redemption or exchange.
Revelation Biosciences, Inc. updated its leadership contracts, tightened governance rules, and obtained key shareholder approvals. The company signed amended three-year employment agreements with its CEO and CFO, increasing change-in-control severance to 2x salary plus target bonus and up to 18 months of COBRA premium reimbursement.
The board adopted amended bylaws adding detailed “Cause” definitions, universal proxy and advance-notice requirements for director nominations, and a formal emergency succession plan for the CEO and CFO. Stockholders elected one Class A director and authorized the board to carry out one or more reverse stock splits within a one-for-two to one-for-250 range, and ratified Baker Tilly US, LLP as auditor for 2026.
Revelation Biosciences, Inc. furnished an updated corporate presentation, dated June 1, 2026, and made it available to the public on its website. The presentation is attached as Exhibit 99.1 to this report under Item 8.01 Other Information and is incorporated by reference.
The company clarifies that the materials in Item 8.01 and Exhibit 99.1 are being furnished, not filed, so they are not subject to certain Exchange Act liabilities and are only incorporated into other filings if specifically referenced. Item 9.01 lists Exhibit 99.1 and an Inline XBRL cover page file as Exhibit 104.
Revelation Biosciences, Inc. reported financial results for the three months ended March 31, 2026. The company recorded a net loss of $3.0 million, or $2.71 per basic and diluted share, and net loss attributable to common stockholders of $8.7 million after $5.7 million in deemed dividends.
Cash and cash equivalents were $14.1 million as of March 31, 2026, up from $10.7 million at year-end 2025, helped by $6.7 million in net proceeds from a January 2026 warrant inducement. Management believes this cash is sufficient to fund operations through the first quarter of 2027.
Operating expenses rose as the company advanced its Gemini programs, with research and development expense of $1.4 million and general and administrative expense of $1.7 million. Revelation also highlighted agreement with the FDA on a single adaptive Phase 2/3 study of Gemini for acute kidney injury and ongoing development efforts in kidney disease, severe burn, and post-surgical infection.
Revelation Biosciences, Inc. reported that stockholders approved the issuance of common shares under its Class J Common Stock Warrants, even when those issuances exceed Nasdaq’s 20% “Exchange Cap” on below-market share issuances. This approval was granted at a Special Meeting held on March 18, 2026.
Under the warrant terms, the expiration date is five years from stockholder approval, so the Class J Common Stock Warrants now expire on March 18, 2031. A quorum was reached with 4,171,735 shares represented out of 10,492,469 shares outstanding and entitled to vote as of the record date.
Revelation Biosciences reported 2025 results showing lower losses, a stronger balance sheet, and progress with its Gemini inflammation program. Net loss for 2025 was $8.9 million, improved from $15.0 million in 2024, as operating cash burn decreased.
Net cash used for operating activities fell to $8.3 million from $18.3 million, while cash and cash equivalents rose to $10.7 million at December 31, 2025 from $6.5 million a year earlier, helped by a May 2025 public offering and a September 2025 warrant inducement.
The company expects its cash to fund operations into the first quarter of 2027. It highlighted positive PRIME study results in late-stage chronic kidney disease, an FDA agreement on a single adaptive Phase 2/3 study of Gemini for acute kidney injury, and planned presentation of Gemini data at a major nephrology conference.
Revelation Biosciences, Inc. entered into warrant exercise inducement agreements with two investors, prompting them to immediately exercise Class I common stock warrants for aggregate gross proceeds of about $7.3 million before advisory fees.
In return, the investors received 17,089,998 pre-split (4,272,500 post-split) new Class J common stock warrants, with an exercise price of $0.86 pre-split ($3.44 post-split). These new warrants are not exercisable until stockholder approval and will then be exercisable for five years. The company plans to use the net proceeds to support clinical development, working capital, and general corporate purposes.
Revelation Biosciences filed an 8-K to share that it has reached agreement with the FDA on an approval pathway for its Gemini program in acute kidney injury (AKI). The company reports that the FDA meeting supported a single adaptive design Phase 2/3 registration study and an approvable composite endpoint, which together outline how the pivotal trial could be structured to support a potential marketing application.
The company also released a press release and an updated corporate presentation, both dated January 21, 2026, and made them available on its website. These materials, furnished as exhibits, provide additional detail on the regulatory path and the AKI program but are not treated as filed financial statements.
Revelation Biosciences, Inc. furnished an 8‑K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025.
The release is included as Exhibit 99.1 under Item 2.02 and will not be treated as “filed” or incorporated by reference unless expressly stated.
Revelation Biosciences (REVB) canceled its adjourned Special Meeting of Stockholders scheduled for October 29, 2025 due to a technical difficulty that prevented some stockholders from voting all of their shares.
The company set a new record date of October 29, 2025 for a new Special Meeting to be held on December 3, 2025. The disclosure is furnished under Item 7.01 (Regulation FD), and a related press release is included as Exhibit 99.1.
Revelation Biosciences (REVB) announced that its Special Meeting of Stockholders held on October 15, 2025 was adjourned to October 29, 2025 because a quorum was not present. The company disclosed this under Regulation FD, noting the information is being furnished, not filed.
The update was provided via an 8-K with an accompanying press release as Exhibit 99.1. The adjournment allows additional time to achieve the required shareholder participation to conduct the meeting’s business.
Revelation Biosciences, Inc. entered into warrant exercise inducement agreements with certain holders of 13,065,000 existing Class H Common Stock Warrants, leading to the cash exercise of warrants for approximately $9.6 million in aggregate gross proceeds at an exercise price of $2.20 per share. In return, the company agreed to issue 13,065,000 new Class I Common Stock Warrants, also with a $2.20 exercise price, which will become exercisable only after stockholder approval and then remain exercisable for five years from that approval date.
The company plans to use the net proceeds to fund clinical development, working capital, and general corporate purposes. The existing warrant share issuance is covered by an effective Form S-1 registration statement, while the new Class I Warrants were issued in a private placement exemption and their underlying shares are expected to be registered for resale on a future Form S-3. Revelation agreed to pay Roth Capital Partners, LLC a cash fee equal to 8% of the aggregate gross proceeds plus expense reimbursement for advisory services related to this transaction.